Preliminary Results of a Phase 1/2, Multi-Center, Open-Label Study (CLL-001) Investigating a Stepwise Dose-Escalation Schedule of Lenalidomide in Relapsed or Refractory Chronic-Lymphocytic-Leukemia

被引：0

作者：

Wendtner, Clemens M. ^{[1
]}

Mahadevan, Daruka ^{[2
]}

Stilgenbauer, Stephan ^{[3
]}

Frankfurt, Olga ^{[4
]}

Bloor, Adrian ^{[5
]}

Bosch, Francesc ^{[6
]}

Uharek, Lutz ^{[7
]}

Furman, Richard R. ^{[8
]}

Gobbi, Marco ^{[9
]}

Gribben, John G. ^{[10
]}

Kimby, Eva K. ^{[11
]}

Sekeres, Mikkael A. ^{[12
]}

Cripe, Larry D. ^{[13
]}

Lombardy, Elyane ^{[14
]}

Shah, Sheetal ^{[14
]}

Moutouh-de Parseval, Laure A. ^{[14
]}

Chanan-Khan, Asher Alban ^{[15
]}

Knight, Robert D. ^{[14
]}

机构：

[1] Univ Cologne, Dept Internal Med 1, Cologne, Germany

[2] Arizona Canc Ctr, Tucson, AZ USA

[3] Univ Ulm, Ulm, Germany

[4] NW Mem Hosp, Robert H Lurie CCC, Chicago, IL 60611 USA

[5] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England

[6] Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain

[7] Charite Univ Med Berlin, Med Clin Hematol Oncol 3, Berlin, Germany

[8] Weill Cornell Med Coll, Dept Hematol Oncol, New York, NY USA

[9] Univ Genova Italy, Genoa, Italy

[10] Barts & London Queen Marys Sch Med & Dent, London, England

[11] Karolinska Inst, Hematol Ctr, Stockholm, Sweden

[12] Cleveland Clin, Cleveland, OH 44106 USA

[13] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA

[14] Celgene Corp, Summit, NJ USA

[15] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

来源：

BLOOD | 2008年 / 112卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：732 / 732

页数：1

共 50 条

[41] A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors
Margaret von Mehren
Carolyn D. Britten
Peter Pieslor
Wayne Saville
Artemios Vassos
Sarah Harris
Gerald R. Galluppi
Mohamed Darif
Zev A. Wainberg
Roger B. Cohen
Stephen Leong
[J]. Investigational New Drugs, 2014, 32 : 518 - 525
[42] Preliminary Results of a Phase 2, Open-Label Study of Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Chronic Lymphocytic Leukemia Relapsed after or Refractory to Ibrutinib or Idelalisib Therapy
Jones, Jeffrey
Mato, Anthony R.
Coutre, Steven
Wierda, William
Choi, Michael Y.
Davids, Matthew S.
Lamanna, Nicole
Barr, Paul
Burns, Kim
Montalvo, Nicholas
Zhu, Ming
Busman, Todd
Potluri, Jalaja
Humerickhouse, Rod A.
Byrd, John C.
[J]. BLOOD, 2015, 126 (23)
[43] A PHASE IB, MULTI-CENTER, OPEN-LABEL, DOSE-ESCALATION STUDY OF ORAL PANOBINOSTAT (LBH589) AND IV BORTEZOMIB IN ADULT PATIENTS WITH MULTIPLE MYELOMA (MM)
Sezer, O.
Kaiser, M.
Siegel, D.
Prosser, I.
Mateos, M. V.
Kangas, M.
Jalaluddin, M.
Bourquelot, P.
Blade, J.
Miguel, J. San
Anderson, K.
Bradner, J.
[J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 176 - 176
[44] A phase 1, multi-center, open-label, dose-escalation and dose expansion study of CBP-1018, a bi-ligand-drug conjugate, in patients with heavily treated advanced solid tumors
Li, Kaiwen
Wu, Junyan
Ye, Suiwen
Liu, Yanqiong
Huang, Hao
Fan, Fan
Lai, Yiming
Zhuang, Suili
Zhou, Liyan
Huang, Robert
Teng, Yan
Chai, Xiaoyan
Shi, Yehui
Huang, Hai
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[45] Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (GEN503): Final Results of an Open-Label, Phase 1/2 Study
Plesner, Torben
Arkenau, Hendrik-Tobias
Gay, Francesca Marianatal
Minnema, Monique C.
Boccadoro, Mario
Moreau, Philippe
Cavenagh, James D.
Perrot, Aurore
Laubach, Jacob
Ahmadi, Tahamtan
de Boer, Carla
Chen, Diana
Chiu, Christopher
Schecter, Jordan
Richardson, Paul G.
[J]. BLOOD, 2017, 130
[46] Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin’s lymphoma: an open-label, multicenter, dose-escalation phase 1 study
Hideki Goto
Koji Izutsu
Daisuke Ennishi
Yuko Mishima
Shinichi Makita
Koji Kato
Miyoko Hanaya
Satoshi Hirano
Kazuya Narushima
Takanori Teshima
Hirokazu Nagai
Kenichi Ishizawa
[J]. International Journal of Hematology, 2022, 116 : 911 - 921
[47] Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label Study
Hari, Parameswaran N.
Shain, Kenneth H.
Voorhees, Peter M.
Gabrail, Nashat
Abidi, Muneer H.
Zonder, Jeffrey
Boccia, Ralph V.
Richardson, Paul G.
Neuman, Linda L.
Dixon, Sandra J.
Prada, Claudia Paba
[J]. BLOOD, 2014, 124 (21)
[48] Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin's lymphoma: an open-label, multicenter, dose-escalation phase 1 study
Goto, Hideki
Izutsu, Koji
Ennishi, Daisuke
Mishima, Yuko
Makita, Shinichi
Kato, Koji
Hanaya, Miyoko
Hirano, Satoshi
Narushima, Kazuya
Teshima, Takanori
Nagai, Hirokazu
Ishizawa, Kenichi
[J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 116 (06) : 911 - 921
[49] A Phase 1, Open-Label, Dose-Escalation and Expansion, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TAK-169 in Patients With Relapsed or Refractory Multiple Myeloma
Kumar, Shaji
Mamuye, Admasu
Dabovic, Kristina
Wang, Jingyuan
Roy, Vivek
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 : S10 - S11
[50] RESULTS OF A PHASE 2, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY OF LENALIDOMIDE IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)
O'Brien, Maureen
Alonzo, Todd
Cooper, Todd
Levine, John
Brown, Patrick
Slone, Tamra
Benettaib, Bouchra
Biserna, Noha
Poon, Jennifer
Quan, Jackie
Simcock, Mathew
Weiss, Daniel
Zimmerman, Linda
Kolb, Edward
[J]. PEDIATRIC BLOOD & CANCER, 2018, 65

← 1 2 3 4 5 →